Affordable Medications Act
Latest action · Jun 12, 2019 Read twice and referred to the Committee on Finance.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedJun 12, 2019
- Passed SenateNot reached
- Passed HouseNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Affordable Medications Act
This bill revises and expands various requirements relating to prescription-drug pricing and affordability. Specifically, the bill
- expands financial reporting requirements for drug manufacturers and establishes corresponding civil penalties for noncompliance;
- adds reporting requirements for certain nonprofit patient-assistance programs;
- requires the Centers for Medicare & Medicaid Services (CMS) to negotiate prices for certain prescription drugs under Medicare;
- requires the Centers for Medicare and Medicaid Innovation within the CMS to test specified models for negotiating drug prices;
- establishes reporting requirements, and corresponding civil penalties for noncompliance, for pharmaceutical companies with respect to spikes in prescription-drug prices;
- establishes an excise tax on prescription drugs subject to price spikes;
- lessens prescription-drug cost-sharing requirements under qualified health plans and group health plans;
- modifies requirements for the importation of prescription drugs;
- requires drug manufacturers to provide drug rebates for drugs dispensed to certain low-income individuals under the Medicare program;
- limits the time frame that trade agreements are required to provide market exclusivity for biological products;
- establishes an innovation incentive fund for new or more effective treatments of bacterial infections;
- establishes a Center for Clinical Research within the National Institutes of Health;
- revises certain time frames and conditions related to drug exclusivity;
- requires the Food and Drug Administration to establish a database of generic drugs; and
- modifies other provisions related to generic drugs, prescription-drug advertising, disclosure of wholesale acquisition prices, and patent-infringement proceedings.
Cosponsors 15
Members who signed on, in the order they did. Signatures ran from Jun 12, 2019 to Sep 9, 2019, with 14 there on the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-MN | Amy Klobuchar | Original | Jun 12, 2019 |
| I-VT | Bernard Sanders | Original | Jun 12, 2019 |
| D-NJ | Cory A. Booker | Original | Jun 12, 2019 |
| D-MA | Elizabeth Warren | Original | Jun 12, 2019 |
| D-RI | Jack Reed | Original | Jun 12, 2019 |
| D-OR | Jeff Merkley | Original | Jun 12, 2019 |
| D-NY | Kirsten E. Gillibrand | Original | Jun 12, 2019 |
| D-NH | Margaret Wood Hassan | Original | Jun 12, 2019 |
| D-CT | Richard Blumenthal | Original | Jun 12, 2019 |
| D-IL | Richard J. Durbin | Original | Jun 12, 2019 |
| D-RI | Sheldon Whitehouse | Original | Jun 12, 2019 |
| D-OH | Sherrod Brown | Original | Jun 12, 2019 |
| D-WI | Tammy Baldwin | Original | Jun 12, 2019 |
| D-NM | Tom Udall | Original | Jun 12, 2019 |
| D-CA | Kamala D. Harris | Sep 9, 2019 |
Actions 2
Everything that happened, newest first.
- Jun 12, 2019Introduced in Senate
- Jun 12, 2019Read twice and referred to the Committee on Finance.
Related bills 10
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 64 | Preserve Access to Affordable Generics and Biosimilars Act | Related bill | Jan 9, 2019 |
| S 73 | End Taxpayer Subsidies for Drug Ads Act | Related bill | Jan 10, 2019 |
| S 97 | Affordable and Safe Prescription Drug Importation Act | Related bill | Jan 10, 2019 |
| S 378 | Stop Price Gouging Act | Related bill | Feb 7, 2019 |
| HR 447 | Affordable and Safe Prescription Drug Importation Act | Related bill | Jan 25, 2019 |
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Administrative law and regulatory procedures
- Canada
- Civil actions and liability
- Congressional oversight
- Department of Health and Human Services
- Digestive and metabolic diseases
- Drug safety, medical device, and laboratory regulation
- Executive agency funding and structure
- Government information and archives
- Government studies and investigations
- Health
- Health care costs and insurance
- Infectious and parasitic diseases
- Inflation and prices
- Intellectual property
- Marketing and advertising
- Medicaid
- Medical research
- Medicare
- National Institutes of Health (NIH)
- Prescription drugs
- Public contracts and procurement
- Retail and wholesale trades
- Sales and excise taxes
- Trade restrictions
- User charges and fees
Text 1
Each version as it was printed, newest first.
- Jun 12, 2019Introduced in Senate
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov.